Erythrocytosis / polycythaemia work-up
polycythaemia w/u · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A raised haematocrit/haemoglobin requires distinguishing true erythrocytosis from apparent (plasma-contracted) polycythaemia, and primary (polycythaemia vera) from secondary causes, because management and thrombotic risk differ markedly.
Red flags
- Thrombosis (arterial or venous, including splanchnic)
- Hyperviscosity symptoms (visual disturbance, headache, confusion)
- Haematocrit markedly elevated
- Splanchnic vein thrombosis (consider occult PV)
- Erythromelalgia with vascular events
Assessment
Differential diagnosis
- Polycythaemia vera (JAK2)
- Secondary (hypoxia, smoking, EPO-secreting tumour, high altitude)
- Apparent/relative polycythaemia (dehydration, obesity, diuretics)
- Congenital high-affinity haemoglobin
- Testosterone/anabolic steroid use
Investigations
- Confirm persistently raised haematocrit/haemoglobin
- JAK2 V617F mutation (and exon 12 if negative but suspicious)
- Serum erythropoietin (low in PV, high in secondary)
- Oxygen saturation / carboxyhaemoglobin (smoking)
- Ferritin, renal and liver function, abdominal imaging for EPO-secreting tumour
- Bone marrow if PV suspected
Management
- Confirm the result is sustained and not spurious
- Assess for symptoms of hyperviscosity and thrombosis risk
- Distinguish apparent from true erythrocytosis (red cell mass rarely needed now)
- Test JAK2 V617F - positivity with other criteria supports polycythaemia vera
- Measure erythropoietin: low suggests PV, raised/normal points to secondary causes
- Screen for secondary drivers: hypoxia, smoking, sleep apnoea, renal/hepatic tumours, exogenous androgens
- Diagnose polycythaemia vera using haemoglobin/haematocrit, JAK2 and marrow criteria
- Manage PV with venesection to target haematocrit <0.45, aspirin, and cytoreduction if high risk
- Treat secondary causes by addressing the underlying stimulus
- Give cardiovascular risk reduction and arrange appropriate follow-up
Drugs & doses
Aspirin 75-100 mg PO once daily (polycythaemia vera)
Therapeutic venesection to keep haematocrit <0.45 (PV)
Hydroxycarbamide 15-20 mg/kg/day PO (high-risk PV cytoreduction)
Ruxolitinib for hydroxycarbamide-resistant/intolerant PV
Disposition
Haematology outpatient work-up; PV managed long term by haematology; treat secondary causes in the relevant speciality.
Complications & pitfalls
- Arterial and venous thrombosis
- Haemorrhage
- Transformation of PV to myelofibrosis or acute leukaemia
- Hyperviscosity
- Pruritus (PV)
Exam pearls
- A low erythropoietin with JAK2 positivity strongly suggests polycythaemia vera
- Target haematocrit below 0.45 to reduce thrombosis in PV
- Smoking and sleep apnoea are common secondary causes
- Unexplained splanchnic thrombosis should prompt JAK2 testing
- Apparent polycythaemia (contracted plasma volume) needs no cytoreduction
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.